Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate

Vignesh T. Packiam, Sanjay G. Patel, Joseph J Pariser, Kyle A. Richards, Adam B. Weiner, Gladell P. Paner, David J. Vanderweele, Gregory P. Zagaja, Scott E. Eggener

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective To compare pathological characteristics, treatment patterns, and survival in patients with ductal adenocarcinoma (DC) compared to those with acinar adenocarcinoma (AC). Materials and Methods Using the National Cancer Database, we identified patients diagnosed with clinically localized (cN0, cM0) pure DC (n = 1328) and AC (n = 751,635) between 1998 and 2011. High-risk AC was defined as Gleason 8-10. Demographic, treatment, pathological, and survival characteristics of patients were compared. Results Compared to patients with Gleason 8-10 AC, those with DC presented with lower mean prostate-specific antigen (10.3 vs 16.2 ng/mL, P <.001), had similar rates (11.7% vs 11.5%, P =.8) of clinical extra-capsular extension (stage ≥ cT3), and were more likely to undergo prostatectomy (54% vs 36%, P <.001). Compared to patients with Gleason 8-10 AC undergoing prostatectomy, those with DC had more favorable pathology: stage ≥ T3 (39% vs 52%, P <.001), fewer positive lymph nodes (4% vs 11%, P <.001), and fewer positive margins (25% vs 33%, P <.001). On Kaplan-Meier analysis, patients with DC had similar 5-year survival (75.0%, 95% confidence interval [CI] [71.7-78.9]) compared to those with Gleason 8-10 AC (77.1%, 95% CI [76.6%-77.6%], P =.2). On Cox multivariable analysis, patients with Gleason 8-10 AC had a similar risk of death compared to those with DC (hazards ratio = 0.92, 95% CI [0.69-1.23], P = 6). Conclusion In this large contemporary population-based series, patients with DC of the prostate presented with lower prostate-specific antigen, had more favorable pathological features, and similar overall survival compared to men with Gleason 8-10 AC.

Original languageEnglish (US)
Pages (from-to)777-782
Number of pages6
JournalUrology
Volume86
Issue number4
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Prostate
Adenocarcinoma
Population
Survival
Confidence Intervals
Prostate-Specific Antigen
Prostatectomy
Kaplan-Meier Estimate
Lymph Nodes
Demography
Databases
Pathology

Cite this

Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. / Packiam, Vignesh T.; Patel, Sanjay G.; Pariser, Joseph J; Richards, Kyle A.; Weiner, Adam B.; Paner, Gladell P.; Vanderweele, David J.; Zagaja, Gregory P.; Eggener, Scott E.

In: Urology, Vol. 86, No. 4, 01.10.2015, p. 777-782.

Research output: Contribution to journalArticle

Packiam, VT, Patel, SG, Pariser, JJ, Richards, KA, Weiner, AB, Paner, GP, Vanderweele, DJ, Zagaja, GP & Eggener, SE 2015, 'Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate', Urology, vol. 86, no. 4, pp. 777-782. https://doi.org/10.1016/j.urology.2015.07.009
Packiam, Vignesh T. ; Patel, Sanjay G. ; Pariser, Joseph J ; Richards, Kyle A. ; Weiner, Adam B. ; Paner, Gladell P. ; Vanderweele, David J. ; Zagaja, Gregory P. ; Eggener, Scott E. / Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. In: Urology. 2015 ; Vol. 86, No. 4. pp. 777-782.
@article{954eec42bf9445f6a197b91f1c49ebfa,
title = "Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate",
abstract = "Objective To compare pathological characteristics, treatment patterns, and survival in patients with ductal adenocarcinoma (DC) compared to those with acinar adenocarcinoma (AC). Materials and Methods Using the National Cancer Database, we identified patients diagnosed with clinically localized (cN0, cM0) pure DC (n = 1328) and AC (n = 751,635) between 1998 and 2011. High-risk AC was defined as Gleason 8-10. Demographic, treatment, pathological, and survival characteristics of patients were compared. Results Compared to patients with Gleason 8-10 AC, those with DC presented with lower mean prostate-specific antigen (10.3 vs 16.2 ng/mL, P <.001), had similar rates (11.7{\%} vs 11.5{\%}, P =.8) of clinical extra-capsular extension (stage ≥ cT3), and were more likely to undergo prostatectomy (54{\%} vs 36{\%}, P <.001). Compared to patients with Gleason 8-10 AC undergoing prostatectomy, those with DC had more favorable pathology: stage ≥ T3 (39{\%} vs 52{\%}, P <.001), fewer positive lymph nodes (4{\%} vs 11{\%}, P <.001), and fewer positive margins (25{\%} vs 33{\%}, P <.001). On Kaplan-Meier analysis, patients with DC had similar 5-year survival (75.0{\%}, 95{\%} confidence interval [CI] [71.7-78.9]) compared to those with Gleason 8-10 AC (77.1{\%}, 95{\%} CI [76.6{\%}-77.6{\%}], P =.2). On Cox multivariable analysis, patients with Gleason 8-10 AC had a similar risk of death compared to those with DC (hazards ratio = 0.92, 95{\%} CI [0.69-1.23], P = 6). Conclusion In this large contemporary population-based series, patients with DC of the prostate presented with lower prostate-specific antigen, had more favorable pathological features, and similar overall survival compared to men with Gleason 8-10 AC.",
author = "Packiam, {Vignesh T.} and Patel, {Sanjay G.} and Pariser, {Joseph J} and Richards, {Kyle A.} and Weiner, {Adam B.} and Paner, {Gladell P.} and Vanderweele, {David J.} and Zagaja, {Gregory P.} and Eggener, {Scott E.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.urology.2015.07.009",
language = "English (US)",
volume = "86",
pages = "777--782",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate

AU - Packiam, Vignesh T.

AU - Patel, Sanjay G.

AU - Pariser, Joseph J

AU - Richards, Kyle A.

AU - Weiner, Adam B.

AU - Paner, Gladell P.

AU - Vanderweele, David J.

AU - Zagaja, Gregory P.

AU - Eggener, Scott E.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective To compare pathological characteristics, treatment patterns, and survival in patients with ductal adenocarcinoma (DC) compared to those with acinar adenocarcinoma (AC). Materials and Methods Using the National Cancer Database, we identified patients diagnosed with clinically localized (cN0, cM0) pure DC (n = 1328) and AC (n = 751,635) between 1998 and 2011. High-risk AC was defined as Gleason 8-10. Demographic, treatment, pathological, and survival characteristics of patients were compared. Results Compared to patients with Gleason 8-10 AC, those with DC presented with lower mean prostate-specific antigen (10.3 vs 16.2 ng/mL, P <.001), had similar rates (11.7% vs 11.5%, P =.8) of clinical extra-capsular extension (stage ≥ cT3), and were more likely to undergo prostatectomy (54% vs 36%, P <.001). Compared to patients with Gleason 8-10 AC undergoing prostatectomy, those with DC had more favorable pathology: stage ≥ T3 (39% vs 52%, P <.001), fewer positive lymph nodes (4% vs 11%, P <.001), and fewer positive margins (25% vs 33%, P <.001). On Kaplan-Meier analysis, patients with DC had similar 5-year survival (75.0%, 95% confidence interval [CI] [71.7-78.9]) compared to those with Gleason 8-10 AC (77.1%, 95% CI [76.6%-77.6%], P =.2). On Cox multivariable analysis, patients with Gleason 8-10 AC had a similar risk of death compared to those with DC (hazards ratio = 0.92, 95% CI [0.69-1.23], P = 6). Conclusion In this large contemporary population-based series, patients with DC of the prostate presented with lower prostate-specific antigen, had more favorable pathological features, and similar overall survival compared to men with Gleason 8-10 AC.

AB - Objective To compare pathological characteristics, treatment patterns, and survival in patients with ductal adenocarcinoma (DC) compared to those with acinar adenocarcinoma (AC). Materials and Methods Using the National Cancer Database, we identified patients diagnosed with clinically localized (cN0, cM0) pure DC (n = 1328) and AC (n = 751,635) between 1998 and 2011. High-risk AC was defined as Gleason 8-10. Demographic, treatment, pathological, and survival characteristics of patients were compared. Results Compared to patients with Gleason 8-10 AC, those with DC presented with lower mean prostate-specific antigen (10.3 vs 16.2 ng/mL, P <.001), had similar rates (11.7% vs 11.5%, P =.8) of clinical extra-capsular extension (stage ≥ cT3), and were more likely to undergo prostatectomy (54% vs 36%, P <.001). Compared to patients with Gleason 8-10 AC undergoing prostatectomy, those with DC had more favorable pathology: stage ≥ T3 (39% vs 52%, P <.001), fewer positive lymph nodes (4% vs 11%, P <.001), and fewer positive margins (25% vs 33%, P <.001). On Kaplan-Meier analysis, patients with DC had similar 5-year survival (75.0%, 95% confidence interval [CI] [71.7-78.9]) compared to those with Gleason 8-10 AC (77.1%, 95% CI [76.6%-77.6%], P =.2). On Cox multivariable analysis, patients with Gleason 8-10 AC had a similar risk of death compared to those with DC (hazards ratio = 0.92, 95% CI [0.69-1.23], P = 6). Conclusion In this large contemporary population-based series, patients with DC of the prostate presented with lower prostate-specific antigen, had more favorable pathological features, and similar overall survival compared to men with Gleason 8-10 AC.

UR - http://www.scopus.com/inward/record.url?scp=84942920030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942920030&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2015.07.009

DO - 10.1016/j.urology.2015.07.009

M3 - Article

C2 - 26196240

AN - SCOPUS:84942920030

VL - 86

SP - 777

EP - 782

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -